Abstract
It is well established that major psychosis (schizophrenia and bipolar disorder) has a strong hereditary basis. However, no unequivocal genetic mutation or polymorphism underlying these disorders has been identified thus far. This paper discusses the role of epigenetics (heritable changes in gene expression not involving changes in DNA sequence) in the pathogenesis of the major psychoses. Importantly, epigenetics offers a conceptual interface between the environment and the genome in the pathogenesis of these disorders. The paper discusses the epigenetically modified genes that are thought to predispose to the development of the major psychoses. The putative environmental factors that can epigenetically modify the genes underlying these disorders are also presented. Finally, the paper offers a framework for epigenetics research applications with considerations over diagnosis, treatment, and prevention of these disorders that have a substantial public health burden throughout the world including the Asia-Pacific region.
Keywords: Disease risk, epigenetics, epigenome, methylation, personalized medicine, psychiatry, psychosis, variability
Current Pharmacogenomics and Personalized Medicine
Title: Epigenetic Basis of Individual Variability to Major Psychosis
Volume: 8 Issue: 3
Author(s): Jacob Peedicayil
Affiliation:
Keywords: Disease risk, epigenetics, epigenome, methylation, personalized medicine, psychiatry, psychosis, variability
Abstract: It is well established that major psychosis (schizophrenia and bipolar disorder) has a strong hereditary basis. However, no unequivocal genetic mutation or polymorphism underlying these disorders has been identified thus far. This paper discusses the role of epigenetics (heritable changes in gene expression not involving changes in DNA sequence) in the pathogenesis of the major psychoses. Importantly, epigenetics offers a conceptual interface between the environment and the genome in the pathogenesis of these disorders. The paper discusses the epigenetically modified genes that are thought to predispose to the development of the major psychoses. The putative environmental factors that can epigenetically modify the genes underlying these disorders are also presented. Finally, the paper offers a framework for epigenetics research applications with considerations over diagnosis, treatment, and prevention of these disorders that have a substantial public health burden throughout the world including the Asia-Pacific region.
Export Options
About this article
Cite this article as:
Peedicayil Jacob, Epigenetic Basis of Individual Variability to Major Psychosis, Current Pharmacogenomics and Personalized Medicine 2010; 8 (3) . https://dx.doi.org/10.2174/187569210792246290
DOI https://dx.doi.org/10.2174/187569210792246290 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Aspects of Lone Atrial Fibrillation: What Do We Know?
Current Pharmaceutical Design Ghetto Poverty and Pollution in Egypt: A Deadly Threat for Western Countries Caused by New and Infectious Mutants. A Cultural, Social and Microbiological Synopsis
Inflammation & Allergy - Drug Targets (Discontinued) Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis
Recent Patents on Anti-Infective Drug Discovery Enzyme Inhibitors
Current Bioactive Compounds Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Development of a Novel and Robust Pharmacological Model of Okadaic Acid-induced Alzheimer’s Disease in Zebrafish
CNS & Neurological Disorders - Drug Targets Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Effectiveness of Long-Term Macrolide Therapy in Cryptogenic Organising Pneumonia
Current Respiratory Medicine Reviews Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs: Clinical Implications
Current Pharmaceutical Design The Cardiovascular Protective Effects of Chrysin: A Narrative Review on Experimental Researches
Cardiovascular & Hematological Agents in Medicinal Chemistry The Effect of Acute Hypoxia on Excitability in the Heart and the L-Type Calcium Channel as a Therapeutic Target
Current Drug Discovery Technologies Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials
Reviews on Recent Clinical Trials Lipoproteins in Atherosclerosis Process
Current Medicinal Chemistry Changes in the Expression of the Alzheimers Disease-Associated Presenilin Gene in Drosophila Heart Leads to Cardiac Dysfunction
Current Alzheimer Research Influence of Dietary Substances on Intestinal Drug Metabolism and Transport
Current Drug Metabolism Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy
Current Medicinal Chemistry Isolation, Synthesis and Biomimetic Reactions of Metalloporphyrinoids in Ionic Liquids
Current Organic Synthesis